Cardiac REperfusion With Intralipid® at Reperfusion
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the benefit of Intralipid® or placebo administered prior to
reperfusion to limit ischemia reperfusion injury as measured by the geometric mean difference
of the release of troponin I over 72 hours after coronary artery bypass.